Information on what's happening now
Ok, so I think everybody's now got the idea that there's been a change of sorts, as in, Leukemia cells in the last biopsy, so
the treatment is being detoured to include something else, to get Margie back into remission.
I found an overview to further make your eyeballs roll back into your head. It's important to keep in mind a couple of things as you're reading this:
1. So far, there is no cure for Leukemia, so a person being treated by "traditional means" ie; by an oncologist that is using the treatments available to them may only have access to traditionally used treatment: chemotherapy being an example.
2. Margie is at a research hospital. Not only are the treatments being used way ahead of the "traditional" but also, treatments for the benefit of not only Margie, but those Leukemia patients that come after her as well as the top notch transplant team members who not only administer treatment but also are there to research and figure out how to beat this crappy disease.
So, the level of care and medical direction is far ahead of what we are typically used to and used to hearing about.
So, I'm (kathleen) am writing some information further explaining Margie's type of transplant but also the treatment that will begin soon so as to put her back into remission. (so that she can have a transplant)
Stay with me: this is equally profound, exciting and cool (mixed with some freaky) all with the goal of getting Margie past Leukemia!
Acute myeloid leukemia (aml) is a malignant disease of the bone marrow. This disease is usually treated with aggressive chemotherapy if patients are fit enough for this treatment. Unfortunately, this chemotherapy cures only a minority of patients. The results are poorer in older patients because the disease might be more resistant to treatment, and pateints are less able to tolerate the aggressive treatment. Bone marrow or stem cell transplants have been performed to try to increase the number of cures by reducing the relapse risk. This procedure has been mainly used in patients undeer the age of 50 because the risks involved in the treatment increase with age. Part of this risk relates to the high doses of chemotherapy and/ or total body irradiation, which are given to the entire body to attempt to kill the cancer cells and prevent rejection of the donor cells.
We (transplant team members) have performed an initial study to test whether stem cell transplants can be done with lower dose treatments in older patients. The aim of this treatment is to eliminate cancer cells by an immune reaction of donor cells against the cancer. We have experiencein more ethan 100 patients treated this way, mainly between the agesof 50 and 72, with a variety of different blood cancers and treated at three collaborating centers. Used by itself, this new appproach appears safer than standard transplants and has often been done mostly in the outpatient department. In most patients engraftment (growth of donor cells) was achieved, and in those followed for more than 2 months rejection of donor cells occurred in only one patient. The main side effect of these transplants has been graft-versus-host disease (GVHD), an immune reaction of the donor cells against the patients body. This experience has encouraged us to further test the effectiveness of this transplant in older patients with AML.
It is known that immune reactions of the donor cells against cancer contribute significantly to the ability to achieve cure after transplantation. One element of this research study will be to test whether immune cells, specifically lymphocytes, from the donor can be used to treat AML. The main reason for using this treatment is the evidence that strong immune responses can occur from donor lymphocytes and remissions from cancer have been reported in patients whose cancer came back after a bone marrow transplant. This type of treatment is called a donor lymphocyte infusion (DLI). It has been shown that it is possible to get complete remissions of the cancer by using DLI. This type of immune response against cancer cells is usually called a graft -versus-leukemia (GVL) effect. Thus one aspect of this treatment will be to establish growth of donor cells in your body in hopes of obtaining a GVL effect. This is achieved by giving treatment to suppress your immune system at the time the stem cell transplant is given. Unfortunately, the same immune responses that lead to a GVL effect can also cause graft-versus-host disease (GVHD), which can manifest itself as skin rashes, nausea, diarrhea and abnormal liver function. It is not possible to clinically measure the amount of GVL that is occurring following a transplant, but evience of GVHD is readily apparent and can be used to establish the presence or absence of GVL. If you do not develop GVHD by 56 to 84 days after the transpnat and have had successful growth of donor cells, we will give you another boost of donor cells in an attempt to maximize the GVL effect. If t here is still no GVHD by 65 days after the first boost of donor cells, we will give you a second, higher dose boost of donor cells.
However, for patients with advanced disease, the GVL effect may not be enough to control the disease. Thus a second aspect of this treatment will be to use a new approach designed to deliver more radiation to your bone marrow ans pleen where leukemia cells live while delivering less radiation to non-leukemic tissue. This is done by attaching ("labeling") radioactive iodine (a molecule which produces radiation) to monoclonal antibodies and injectivng theminto the body using your Hickman catheter. Monoclonal antibodies are special proteins made by mouse cells grown in sterile broth, and are attracted to target molecules on the surface of the leukemic cells as well as normal cells in the bone marrow and spleen. By attaching the radioactive isotope to the antibodies, we hope that hte antibody will carry the radiation to leukemic cells and kill them. We have treated over 70 patients with this technique on other research studies for younger patients, combining the radiolabeled antibody with conventional transplant treatments. In this study, we will combine the radiolabeled antibody with the low -dose immunosuppressive therapy in an attempt to kill many of your leukemia cells so that the GVL effect has a chance to kill cells remaining after treatment.
Still with me?
That's an overview of treatment for AML. It reads a little backwards, as mom will be given the antibody therapy first, then onto transplant. Needless to say, your positive thoughts and prayers are appreciated- I personally visualize an aura around her that represents her success and eventual transcendence over Leukemia.
Susie D, thank you for your beautiful thoughts- my parents love for eachother is so apparent as seeing them hold eachother up through this is inspiring as it would be no other way.
Love, K
p.s. , I would like to take just a moment to encourage anyone that has been reading but not commenting to take the next step... click your mouse on that comment link right below here...it's easy. I recently highlighted it in red. ( need extra motivation? you'll be published!)
really, just click it...now... do it. I promise, your computer will not blow up. if you need help with it, email me!
artgirl62@earthlink.net